1. Home
  2. TITN vs CBIO Comparison

TITN vs CBIO Comparison

Compare TITN & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Titan Machinery Inc.

TITN

Titan Machinery Inc.

N/A

Current Price

$17.32

Market Cap

477.0M

ML Signal

N/A

CBIO

Crescent Biopharma Inc.

N/A

Current Price

$12.10

Market Cap

389.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TITN
CBIO
Founded
1980
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
477.0M
389.7M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
TITN
CBIO
Price
$17.32
$12.10
Analyst Decision
Hold
Strong Buy
Analyst Count
4
6
Target Price
$21.50
$26.67
AVG Volume (30 Days)
145.0K
170.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,702,122,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.50
$8.72
52 Week High
$21.75
$17.39

Technical Indicators

Market Signals
Indicator
TITN
CBIO
Relative Strength Index (RSI) 39.93 57.01
Support Level $15.32 $11.88
Resistance Level $20.91 $13.37
Average True Range (ATR) 0.96 0.99
MACD -0.32 0.12
Stochastic Oscillator 12.71 63.66

Price Performance

Historical Comparison
TITN
CBIO

About TITN Titan Machinery Inc.

Titan Machinery Inc owns and operates a network of full-service agricultural and construction equipment stores. The company sells and repairs agricultural equipment, including machinery and attachments for large-scale farming and home and gardening purposes, as well as construction equipment. It operates through the following segments: The Agriculture segment sells, services, and rents machinery and related parts and attachments, for uses ranging from large-scale farming to home and garden use, The construction segment sells, services, and rents machinery, and related parts and attachments, for uses ranging from heavy construction to light industrial machinery use, and the Europe and Australia segments.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: